Skip to main content
. 2023 Nov 14;29(1):27–35. doi: 10.1007/s10147-023-02422-x

Table 3.

Reasons for discontinuation of treatment

Total (N = 64)
Study completion due to drug approval 40 (62.5)
Progressive disease per RECIST version 1.1 15 (23.4)
Clinical progression 4 (6.3)
AEs 3 (4.7)
Death 2 (3.1)

Data are shown as n (%)

AEs adverse events; RECIST response evaluation criteria in solid tumors